Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens.
about
Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routesInduction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathwaysVirus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.Adjuvanted influenza vaccine administered intradermally elicits robust long-term immune responses that confer protection from lethal challenge.Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV diseaseRecombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease.Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine.Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteinsCo-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.Intranasal delivery of vaccines against HIV.Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults.Preparation of mucosal nanoparticles and polymer-based inactivated vaccine for Newcastle disease and H9N2 AI viruses.T cell-dependent and -independent IgA responses: role of TLR signalling.Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.
P2860
Q22241377-100D2B85-8A3F-417A-B1A0-9D89C90B6344Q28397551-2A3D780D-3C36-4F01-A1C6-DEBD769711ABQ30359424-06A28E81-8161-4F99-A3EF-2877A8C373C0Q33598298-A6DD6822-CBEA-4A9B-AC91-6668ACD56889Q35070176-B9EFEC7C-FA69-4FF5-96D2-BF8154EB31B7Q35070505-F07E9548-AA0C-4850-AB65-99E915E82CFDQ35277985-7D714E27-1D10-4436-9E55-49555838B941Q35985896-9B1452E0-0F34-4EF6-BD3D-0C80CA02E175Q36030772-9FD443A3-A142-42FD-A3BD-1FB9B44DE30EQ36409054-2D0F7A0F-F842-45B2-B7A7-3A860C20827FQ37530383-D2867830-7244-40B3-8AA9-4D341833E508Q37703366-F4FE6EA6-D30F-452E-B157-300AD39198F7Q37744904-7C91C16E-922C-45B3-9BA5-1B0217D33510Q38461061-B966B308-7ED9-4281-B12C-CA2D96BD2C42
P2860
Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Intranasal immunization with i ...... virus-like particle antigens.
@en
Intranasal immunization with i ...... virus-like particle antigens.
@nl
type
label
Intranasal immunization with i ...... virus-like particle antigens.
@en
Intranasal immunization with i ...... virus-like particle antigens.
@nl
prefLabel
Intranasal immunization with i ...... virus-like particle antigens.
@en
Intranasal immunization with i ...... virus-like particle antigens.
@nl
P2093
P2860
P1433
P1476
Intranasal immunization with i ...... y virus-like particle antigens
@en
P2093
Lizheng Guo
Richard W Compans
Sang-Moo Kang
P2860
P304
P356
10.1128/JVI.78.18.9624-9632.2004
P407
P577
2004-09-01T00:00:00Z